US FDA Gives 1st Nod for Lenvima/Keytruda Combo as 2nd-Line Therapy for Endometrial Carcinoma

The US FDA approved on September 17 the combination therapy of Eisai’s multi-kinase inhibitor Lenvima (lenvatinib) plus US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of patients with advanced endometrial carcinoma, marking the first approval for the combo, the...read more